摘要
目前国内外法规均要求对药物遗传毒性杂质进行控制,当缺乏致突变、致癌性数据时,制药企业大多以商业软件对杂质进行评估,评估费用高昂。FDA推荐了非商用的评估软件,并接受其评估结果,本文对非商用评估软件进行介绍,并以实例对商用与非商用软件预测结果进行对比评价,结果表明所测非商用软件预测结果具有一定参考价值,其参考使用或可节省成本。
At present,both domestic and foreign regulations require the control of genotoxic impurities in drugs.When there is a lack of mutagenicity and carcinogenicity data,pharmaceutical companies mostly use commercial softwares to evaluate impurities,which is expensive.FDA has recommended a non-commercial evaluation software and accepted its evaluation results.This article introduces the non-commercial evaluation software and evaluates the prediction results of commercial and non-commercial softwares through examples.The results show that the prediction results of the non-commercial software has certain reference value and can be promoted for use to save enterprise costs.
作者
李杰
江娟
丁锐
喻欢欢
LI Jie;JIANG Juan;DING Rui;YU Huanhuan(Key Laboratory of Chongqing Industry and Informatization,Southwest Pharmaceutical Co.,Ltd.,Chongqing 400038,China;Chengdu Yukang Science and Technology Co.,Ltd,Chengdu 610000,China;NMPA Key Laboratory for Quality Monitoring of Narcotic Drugs and Psychotropic Substances,Chongqing Institute for Food and Drug Control,Chongqing 401121,China)
出处
《药学与临床研究》
2024年第3期283-288,共6页
Pharmaceutical and Clinical Research
基金
重庆市自然科学基金博士后科学基金项目(cstc2021jcyj-bshX0031)。
关键词
杂质
遗传毒性
(定量)构效关系
警示结构
非商用
替米沙坦
Impurities
Genotoxicity
(Quantitative)Structure-Activity Relationships
Alert structure
Non-commercial
Telmisartan